INVESTOR RESOURCES
Project Twenty21 - Key Learnings
Missed the webcast with Professor David Nutt, Founder of Drug Science and Tejinder Virk, President of Khiron Europe?
There was lots to learn about how the two organizations are working together on Project Twenty21, Europes first and largest medical cannabis registry.
Read More
There was lots to learn about how the two organizations are working together on Project Twenty21, Europes first and largest medical cannabis registry.
Spotlight on Khiron: UK Set to Experience Highest EU Medical Cannabis Growth
With an eye on global expansion, Khiron became the exclusive Latin American company participating in Project Twenty 21.
Read More
Spotlight on Khiron: The Medical Cannabis Leader in Colombia with Global Reach
Our primarily operations are in Latin America, with a market of 620 million people in the region, where we are revenue generating, but we have also operations, revenues, and partnerships spanning 7 countries and 3 continents - North America, South America, and Europe.
Read More
Khiron: Investment Highlights 2020
As Khiron shifts toward the sales-execution phase of its business plan, it is targeting markets it perceives as having the greatest near-term revenue potential and ROIC; these countries include Colombia, Brazil, Peru, the UK, and Germany, where sales have commenced or are expected.
Read More
INVESTOR CONTACT INFORMATION
Company
Khiron Life Sciences Corp.
100 King Street West
Suite 1600
Toronto, Ontario M5X 1A9
Canada
Investor Relations
Paola Ricardo
T: 1 (647) 556-5750
investors@khiron.ca
Transfer Agent
TSX Trust Company
www.tsxtrust.com
Auditor
BDO Canada LLP
www.bdo.ca
Legal Counsel
Gowling WLG (Canada) LLP
gowlingwlg.com
Media Contact
Carolina Gomez
Communications LatAm
mgomez@khiron.ca
Peter Leis
Communications Europe
pleis@khiron.ca
FAq’s
Looking for some fast answers?
We have you covered! Find our most frequently asked questions here. If you don’t find your answer, we’re always happy to connect with you. Write us at investors@khiron.caTrading
When did Khiron Life Sciences Corp. go public?
Khiron completed its RTO with Adent Capital Corp. on May 16, 2018 and commenced trading on the TSX Venture on May 24, 2018 under the ticker “KHRN”.
What is the ticker symbol for Khiron Life Sciences Corp.?
The Company’s shares are listed on the TSX Venture Exchange (“TSX-V”) under the symbol “KHRN”, the OTCQX Best Market (“OTCQX”) under the symbol “KHRNF” and on the Frankfurt Stock Exchange (“FSE”) under the symbol “A2JMXC”.
Where is the company incorporated?
Khiron Life Sciences Corp. (formerly Adent Capital Corp.) was incorporated under the Business Corporations Act (British Columbia) on May 16, 2012.
Khiron PrivateCo (the operating entity and target company in the RTO Qualifying Transaction) was incorporated on February 17, 2017.
Who is Khiron’s transfer agent?
TSX Trust Company
How many shares are issued and outstanding?
Share information and trading information can be found here.
Are shares in the company currently in a lockup period?
Please refer to our latest AIF on SEDAR for latest share escrow information.
Where can I find information on Khiron insider ownership?
Canadian Insider and SEDI provide free tracking of insider transactions.
Total insider holdings are also available in summary format on Yahoo Finance.
Where are Khiron’s Corporate headquarters?
100 King Street West Suite 1600 Toronto, Ontario M5X 1A9 Canada
What is Khiron’s fully diluted share count?
Our fully diluted share count is available on our latest corporate presentation.
Financials
Who are Khiron’s independent auditors?
BDO Canada LLP
What is Khiron’s fiscal year end?
December 31st
Where can I find Khiron’s financial reports?
Khiron’s financial results can be found here.
Are there equity analyst reports on the company available to send or download?
Details regarding analyst coverage can be found here.
ESG
Where can I find Khiron ESG Report?
What guidelines does Khiron use for its ESG Report?
Khiron is aligned to international best practices such as: UN Sustainable Development Goals, UN Global Compact, GRI Standards, UN Guiding Principles on Business & Human Rights